Dexamethasone and Fentanyl Transdermal Patch: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Dexamethasone
No brand names on recordFentanyl Transdermal Patch
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms
Interaction Deep Dive
Concomitant use of fentaNYL with a CYP3A4 inducer may reduce plasma concentrations of fentaNYL resulting in reduced efficacy of fentaNYL or onset of opioid withdrawal syndrome in a patient who had developed physical dependence to fentaNYL. If concomitant use is required, monitor for signs of opioid withdrawal and consider increasing the dosage of fentaNYL until stable drug effects are achieved. Upon discontinuation of the CYP3A4 inducer, plasma concentrations of fentaNYL will increase, which may increase or prolong the therapeutic and adverse effects of fentaNYL, including the risk of serious respiratory depression. If a CYP3A4 inducer is discontinued, consider fentaNYL dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation1432.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of fentaNYL
Literature reports
1 report — tap to read
a) A 64-year-old man receiving rifAMPin, a strong CYP3A4 inducer 5, was not able to achieve pain control with optimized doses of transdermal fentaNYL and rescue pain medications until he was switched to morphine. The patient, who had colon cancer, was receiving rifAMPin 450 mg/day as part of an antitubercular regimen for pulmonary tuberculosis. Despite dose increases from 0.6 mg/day of fentaNYL up to 2.5 mg/day along with rescue medication, pain control was not achieved. When fentaNYL was switched to sustained-release oral morphine at a relative analgesic dose to fentaNYL (180 mg/day), pain control was achieved. Subsequently, however, the patient experienced a disturbance in consciousness, which was considered to be a morphine side effect. Based on the Naranjo probability scale, rifAMPin possibly caused the lack of response to fentaNYL 6.
Common questions
Can I take Dexamethasone and Fentanyl Transdermal Patch together?
Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dexamethasone and Fentanyl Transdermal Patch interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Dexamethasone or Fentanyl Transdermal Patch need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (6)
- Product Information: DURAGESIC(R) transdermal system, fentanyl transdermal system. Janssen Pharmaceuticals Inc (per manufacturer), Titusville, NJ, 2018. DailyMed
- Product Information: ACTIQ(R) oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2023. DailyMed
- Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Hospira Inc (per FDA), Lake Forest, IL, 2023. DailyMed
- Product Information: FENTORA(R) buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2023.
- Certara Drug Interactions Solutions: Certara Drug Interaction Database (DIDB(R)). Princeton, NJ: Certara, May 2024.
- Morii H, Chiba M, Konishi H, et al: Failure of pain control using transdermal fentanyl during rifampicin treatment. J Pain Symptom Manage 2007; 33(1):5-6. PubMed
Keep reading about Dexamethasone
Keep reading about Fentanyl Transdermal Patch
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist